ClinicalTrials.gg
Not yet recruitingNCT06525389LAmB-FASTUpdated Sep 21, 2026

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

A Phase 3 interventional study of Liposomal Amphotericin B (LAmB) and Flucytosine (5FC) in Talaromycosis, sponsored by Duke University. Not yet recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Duke University · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:

  1. Is induction therapy using a single 10 mg\/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
  2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
  3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
Read the detailed description

Talaromycosis (formerly known as penicilliosis) is caused by the dimorphic fungus Talaromyces marneffei (Tm) endemic in Southeast Asia where it is a leading the cause of death among people with advanced HIV disease (AHD, CD4 count \<200 cells/mm3 and/or WHO disease stage III or IV). Despite the mortality on treatment as high as 30%, current treatment options are limited to just two drugs: amphotericin B deoxycholate (DAmB) - which has substantial toxicity, and itraconazole - which has poor bioavailability.

As a roadmap to identify safer and more effective antifungal strategies, LAmB-FAST applies major advances made in HIV-associated mycoses to accelerate treatment for HIV-associated talaromycosis. First, clinical trials in cryptococcosis showed that shorter courses (5 to 7 days) of DAmB was as effective and less toxic than the standard 14-day course of DAmB. The recent AMBITION cryptococcal meningitis showed that a single 10 mg/kg dose of liposomal amphotericin B (LAmB) was as effective as 7 to 14 days of DAmB but had 30% less toxicity, leading to rapid endorsement by the WHO as the first-line therapy for cryptococcal meningitis in 2022. A single LAmB induction therapy strategy has also been demonstrated in a phase II HIV-associated histoplasmosis trial which showed that a single 10 mg/kg dose of LAmB had similar mortality compared to 2 doses or 14 daily doses of LAmB. Second, the addition of flucytosine (5FC) to DAmB has been shown to improves fungal clearance in the cerebrospinnal fluid and survival of patients with cryptococcal meningitis. These advances in other HIV-associated mycoses lead us to hypothesize that 1) a single 10mg/kg dose of LAmB will be superior to 14 days of DAmB and 2) the addition of 5FC will be superior to DAmB or LAmB alone in the induction therapy of talaromyosis.

LAmB-FAST will test three related but independent specific aims: AIM 1: To determine if a single 10mg/kg dose of LAmB is superior to 14 days of DAmB in Tm complication-free survival. AIM 2:

To determine if combination therapy with 5FC is superior to DAmB or LAmB alone in Tm complication-free survival.

The primary outcome (for both AIM 1 and AIM 2) is hazard of a composite of death, Tm complications, and adverse events (AEs) grade 3 or higher.

The secondary outcomes include:

  1. All-cause mortality;
  2. Fungal clearance rate over first 14 days;
  3. A novel 4-scale hierarchical outcome of i. Mortality, ii. Tm complications, iii. AEs grade 3, iv. Quality of life scores;
  4. Rates of Tm DNA and Tm antigen decline over first 12 weeks.

AIM 3 will leverage access to a well-characterized and treated talaromycosis cohort in AIM 1 and AIM 2 to conduct a follow-on nested randomized controlled sub-study testing whether a HIV viral load guided strategy of stopping itraconazole chemoprophylaxis (STOP SHORT) is non-inferior to the current CD4 guided strategy in the prevention of talaromycosis relapse and death.

02

Conditions studied

  • Talaromycosis

Keywords

  • Penicilliosis
  • Talaromyces marneffei infection
  • Penicillium marneffei infection
03

In context

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • infected adults (age greater or equal to 18), on ART or no ART
  • Definitive talaromycosis confirmed by microscopy, histology, or culture

Exclusion criteria

Exclusion Criteria:

  • Known severe allergy to AmB or 5FC
  • \<500 cells
  • Concurrent cryptococcal or TB meningitis
  • Received > 2 doses of DAmB
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
428 participants (estimated)

Study arms

  • Active comparator
    Deoxycholate Amphotericin B (DAmB) plus Flucytosine (5FC) placebo

    DAmB (0.7mg/kg/d IV x 14 days) + 5FC placebo (25 mg/kg oral 3x daily x 14 days)

    Drug: Flucytosine (5FC) placebo pill · Drug: Deoxycholate Amphotericin B (DAmB)

  • Experimental
    Deoxycholate Amphotericin B (DAmB) plus Flucytosine (5FC)

    DAmB (0.7 mg/kg/d IV x 14 days) + 5FC (25 mg/kg oral 3x daily x 14 days)

    Drug: Flucytosine (5FC) · Drug: Deoxycholate Amphotericin B (DAmB)

  • Experimental
    Liposomal Amphotericin B (LAmB) plus Flucytosine (5FC) placebo

    LAmB (10 mg/kg IV x 1 dose) + 5FC placebo (25 mg/kg oral 3x daily x 14 days)

    Drug: Liposomal Amphotericin B (LAmB) · Drug: Flucytosine (5FC) placebo pill

  • Experimental
    Liposomal Amphotericin B (LAmB) plus Flucytosine (5FC)

    LAmB (10 mg/kg IV x 1 dose) + 5FC (25 mg/kg oral 3x daily x 14 days)

    Drug: Liposomal Amphotericin B (LAmB) · Drug: Flucytosine (5FC)

Interventions

  • Antifungal dosed at 10 mg/kg/day IV x one single dose.

  • Antifungal dosed at 25mg/kg oral 3x daily.

  • DrugFlucytosine (5FC) placebo pill

    Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.

  • DrugDeoxycholate Amphotericin B (DAmB)

    Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.

06

What researchers measure

Primary outcomes

  1. Time from enrollment to a composite of poor outcomes

    Poor outcomes are defined as of death, talaromycosis complications (defined as relapse, immune inflammatory reconstitution inflammatory syndrome \[IRIS\], wasting syndrome \[\>10% weight loss from enrollment\], re-hospitalization, and grade 3 or higher adverse events

    Time frame: up to 24 weeks

Secondary outcomes

  1. All cause mortality

    Time frame: up to 24 weeks

  2. Fungal clearance rate as measured by early fungicidal activity (EFA) in log10 CFUs/mL/day

    Time frame: 14 days

  3. Composite ordinal desirability of outcome ranking (DOOR) scale

    All-cause mortality, Talaromycosis complications and adverse events grade 4, Adverse events grade 3, and Quality of Life (QOL) utility scores by EQ5D scale.

    Time frame: over 24 weeks

  4. Change in Talaromyces marneffei DNA in copies/mL/week

    Time frame: baseline to 24 weeks

  5. Change in Talaromyces marneffei antigen in µg/mL/week

    Time frame: baseline to 24 weeks

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing with the scientific community will be carried out according to the FAIR Guiding Principles and spirit of open-access. Previously published data sets will be made available to the scientific community upon request after agreement by the Trial Steering Commitee. The Duke Data Manager will deposit the de-identified master data file into the Duke Research Data Repository (RDR), an openly accessible preservation archive maintained by the Duke University Libraries.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data will become available when all primary and secondary analyses are completed and published and will be available in the Duke Research Data Repository (RDR) indefinitely

Access criteria: Contact PI

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Sep 2030, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2024
First posted
Jul 29, 2024
StartEst.
Nov 2026
Primary completionEst.
Sep 1, 2030
CompletionEst.
Sep 1, 2031
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06525389
Lead sponsor
Duke University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID), Pham Ngoc Thach University of Medicine, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, National Hospital for Tropical Diseases, Hanoi, Vietnam, Bach Mai Hospital, Gilead Sciences, Viatris Inc.
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Nov 2026 (estimated)
Primary completion
Sep 1, 2030 (estimated)
Completion
Sep 1, 2031 (estimated)
Last update
Sep 21, 2026

Study contacts

Thuy Le, MD, PhD
Contact
thuy.le@duke.edu
919-668-5053
Thuy Le, MD, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Liposomal amphotericin B · Flucytosine

Start the discussion